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Abstract
Background: Hepatitis A virus (HAV), an atypical Picornaviridae that causes acute hepatitis in
humans, grows poorly in cell culture and in general does not cause cytopathic effect. Foreign
sequences have been inserted into different parts of the HAV genome. However, the packaging size
limit of HAV has not been determined. The purpose of the present study is to investigate the
maximum size of additional sequences that the HAV genome can tolerate without loosing
infectivity.
Results: In vitro T7 polymerase transcripts of HAV constructs containing a 456-nt fragment coding
for a blasticidin (Bsd) resistance gene, a 1,098-nt fragment coding for the same gene fused to GFP
(GFP-Bsd), or a 1,032-nt fragment containing a hygromycin (Hyg) resistance gene cloned into the
2A-2B junction of the HAV genome were transfected into fetal Rhesus monkey kidney (FRhK4)
cells. After antibiotic selection, cells transfected with the HAV construct containing the resistance
gene for Bsd but not the GFP-Bsd or Hyg survived and formed colonies. To determine whether
this size limitation was due to the position of the insertion, a 606 bp fragment coding for the
Encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) sequence was cloned into
the 5' nontranslated (NTR) region of HAV. The resulting HAV-IRES retained the EMCV IRES
insertion for 1-2 passages. HAV constructs containing both the EMCV IRES at the 5' NTR and the
Bsd-resistance gene at the 2A-2B junction could not be rescued in the presence of Bsd but, in the
absence of antibiotic, the rescued viruses contained deletions in both inserted sequences.
Conclusion: HAV constructs containing insertions of approximately 500-600 nt but not 1,000 nt
produced viable viruses, which indicated that the HAV particles can successfully package
approximately 600 nt of additional sequences and maintain infectivity.
Background
Hepatitis A virus (HAV), a member of the Picornaviridae
family, causes acute hepatitis in humans. The 27-32 nm
non-enveloped HAV icosahedral particles encapsidate a
7.5 kb single-stranded positive-sense RNA genome [1],
which contains a long open reading frame (ORF) flanked
by 5' and 3' end non-translated regions (NTR). The long
5' NTR of approximately 750 nucleotides (nt) has a com-
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plex structure and contains an internal ribosome entry site
(IRES) required for viral translation. The 3' NTR is short
and ends in a poly(A) tail [2]. The HAV long ORF encodes
a polyprotein of approximately 250 kDa that undergoes
co- and post-translational processing into smaller struc-
tural (VP0, VP3, and VP1-2A) and non-structural (2B, 2C,
3A, 3B, 3C, and 3D) proteins [3,4]. HAV 3C is a cysteine
proteinase (3Cpro) responsible for most of the polyprotein
cleavages and is the only protease coded in the HAV
genome [5-9]. The 2A-2B junction is the primary cleavage
site of the HAV polyprotein processed by 3Cpro [9,10]. The
VP0 undergoes structural cleavage, and an unknown host
cellular protease cleaves the VP1-2A junction [11].
HAV is a hepatotropic virus transmitted through the fecal-
oral route. Pathogenesis of HAV is poorly understood,
and it is unclear whether the virus needs to replicate in
extra-hepatic sites before reaching the liver. After binding
to its cellular receptor HAVCR1 [12,13], the HAV genome
is delivered to the cytoplasm by an unknown mechanism.
Once in the cytoplasm, the HAV genome is translated,
transcribed, and encapsidated without in general causing
cytopathic effect. The virus is eliminated by the immune
system and does not establish chronic infection. Inacti-
vated HAV vaccines are safe and effective, and are cur-
rently used in most of the world to prevent and treat HAV
infection [1,14,15].
Considerable interest has been devoted to develop HAV as
an expression vector for combination vaccines, expression
of proteins in the liver, and basic research on this poorly
understood human pathogen. We have previously shown
that replication-competent HAV constructs containing
inserts of 60-81 nt coding for malaria and FLAG-tag
epitopes at the N-terminus of the HAV polyprotein were
stable for at least 6 passages [16]. An HAV recombinant
containing 420-nt insertion at the 2A-2B junction was sta-
ble for up to five passages [10]. HAV constructs carrying a
seven amino acid human immunodeficiency virus gp41
epitope at the surface of the HAV particles elicited an
immune response against gp41 in infected animals
[17,18]. Recently, we showed that a 456-nt fragment cod-
ing for a blasticidin (Bsd) resistant gene inserted at the 2A-
2B junction of wild type HAV was stable for 9 passages
[19], conferred Bsd resistance to infected cells, and was
used to develop an antibiotic resistance titration assay to
evaluate anti-HAV antibodies in preparations of human
immunoglobulins [20]. Although foreign sequences have
been successfully inserted into different parts of the HAV,
the packaging size limit of HAV has not been determined.
To study the maximum size of foreign sequences that HAV
could tolerate, we cloned exogenous sequences into the
2A-2B junction and/or N-terminus of the polyprotein. A
456-nt fragment coding for a Bsd resistance gene was engi-
neered into the 2A-2B junction of HAV and maintained
for 25 passages with or without antibiotic selection. A
recombinant HAV containing the Encephalomyocarditis
(EMCV) internal ribosome entry site (IRES) of 606 nt
cloned at the 5'NTR between the HAV IRES and the initi-
ation codon of the HAV polyprotein only maintained the
insert for a few passages. However, recombinant HAV con-
stucts containing approximately 1,000 nt at the 2A-2B
junction or both the EMCV IRES at the 5'NTR and the Bsd
resistance gene at the 2A-2B junction could not be rescued
from transfected cells. Our results indicated that HAV has
a restricted packaging size limit that can accommodate
approximately 600 nt of additional sequences.
Results
Insertions at the 2A-2B junction
To determine the packaging size limit of the HAV genome,
we inserted foreign sequences into a 66-nt polylinker
engineered between 3Cpro cleavage sites at the 2A-2B junc-
tion of the HAV cDNA in pHAVvec9 [19] (Figure 1). A
396-nt fragment containing a Bsd resistance gene coding
for a Bsd deaminase, a 1098-nt fragment coding for the
same resistance gene fused to the GFP protein (GFP-Bsd),
or a 1032-nt fragment containing a hygromycin (Hyg)
resistance gene coding for a hygromycin-phosphotrans-
ferase were inserted into the polylinker of pHAVvec9, and
termed pHAVvec9-Bsd, pHAVvec9-GFP-Bsd, and
pHAVvec9-Hyg, respectively (Figure 1). All the inserts
lacked translation initiation and termination codons to
Schematic representation of HAV constructs containing  insertions in the 2A-2B junction Figure 1
Schematic representation of HAV constructs con-
taining insertions in the 2A-2B junction. Antibiotic 
resistance genes were cloned the 2A-2B junction of the HAV 
genome in pHAVvec9 [19]. This plasmid contains a polylinker 
coding for SalI, SnaBI, and KpnI restriction sites flanked by Gly 
hinges (grey color letters) and HAV 3Cpro cleavage site 
(arrows) engineered into 2A-2B junction of pT7HAV. The 
blasticidin resistance gene (Bsd) coding for blasticidin deami-
nase, green fluorescent protein (GFP)-Bsd fusion protein, and 
hygromycin resistance gene (Hyg) coding for hygromycin 
phosphotransferase were cloned into the SalI and KpnI sites 
in the polylinker of pHAVvec9, and the resulting plasmids 
were termed pHAVvec9-Bsd, pHAVvec9-GFP-Bsd, and 
pHAVvec9-Hyg, respectively.
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allow expression of the coded proteins as part of the HAV
polyprotein. To rescue viruses, T7 polymerase in vitro tran-
scripts of the HAV constructs were transfected into FRhK4
cells. A day after transfection, cells were split 1:6 and
grown in medium that contained Bsd 0.5-3 μg/ml or
hygromycin 25-250 μg/ml. As expected, some cells trans-
fected with transcripts from pHAVvec9-Bsd survived selec-
tion with 1 μg/ml Bsd and developed colonies (Figure
2A). However, cells transfected with the T7 in vitro tran-
scripts from pHAVvec9-GFP-Bsd did not survive antibiotic
selection, show GFP fluorescence, or produce infectious
virus even without Bsd selection. Cells transfected with in
vitro transcripts from pHAVvec9-Hyg also did not survive
antibiotic selection. A virus stock termed HAVvec9-Bsd
was prepared from these Bsd-resistant cells and used to
infect naïve FRhK4 cells in the presence of 2 μg/ml Bsd.
Cells infected with HAVvec9-Bsd but not mock-infected
cells survived selection with Bsd, indicating that HAVvec9-
Bsd was infectious. However, HAVvec9-Bsd produced 1-
1.5 log less virus than HAVvec9 and parental HAV/7 [19].
The stability of Bsd gene in HAVvec9-Bsd virus was
assessed during 25 serial passages in the absence of Bsd.
RT-PCR (Figure 2B) and nucleotide sequence analysis
(data not shown) revealed that the Bsd gene insert was sta-
ble during the 25 serial passages in FRhK4 cells. These
data suggested that HAV could tolerated insertions of
approximately 500-1,000 nt at the 2A-2B junction
Insertions at the 5' NTR
To assess whether the packaging size limitation of 500-
1,000 nt was site-specific, we inserted a nt fragment into
the 5' NTR of the HAV genome between the HAV IRES and
the initiation codon of the HAV polyprotein. We chose
the EMCV IRES because it is a strong ribosome entry site
compared to the weak HAV IRES [21,22] and has been
widely used in other viral systems [23-29]. We hypothe-
sized that a virus with both IRESes would have a transla-
tion advantage compared to the HAV IRES alone. The
EMCV IRES 606-nt fragment was cloned adjacent to the
polyprotein initiation codon to assure that it would drive
translation of the HAV polyprotein (Figure 3). FRhK4 cells
were transfected with T7 transcripts of the double IRES
HAV construct. After two weeks of incubation, IF analysis
revealed that 10% of the cells had the characteristic cyto-
plasmic granular fluorescence of HAV-infected cells com-
pared to 100% of the cells transfected with pHAVvec9 or
HAVvec9-Bsd transcripts (Figure 4A). A virus stock was
prepared and termed HAV-IRES, and the presence of the
EMCV IRES was assessed by RT-PCR analysis (Figure 4B).
To do so, viral particles were purified by sedimentation
through a 40% sucrose cushion, and viral RNA was
extracted from the pellet. As a negative control, the same
amount of transfected T7 RNA transcripts (20 μl) was
purified in parallel by sedimentation through a 40%
sucrose cushion, and RNA was extracted from the pellet.
As a positive RT-PCR control, we used RNA extracted from
purified HAV/7 particles. RT-PCR analysis showed that
the HAV-IRES but not HAV/7 particles contained the
expected 600 nt EMCV IRES fragment, which was verified
by automated nucleotide sequencing. RT-PCR fragments
were not amplified from the negative control sample.
These data indicated that the 606-nt EMCV IRES insert
was packaged into the HAV-IRES particles. To further
assess the stability of the inserted EMCV-IRES, we per-
formed serial passages of HAV-IRES in FRhK4 cells at
weekly intervals. At each cell passage, a virus stock was
produced and analyzed by RT-PCR as described above.
After 2 passages, most of the EMCV IRES was deleted leav-
ing only a small insert of 21 nt (data not shown). These
data indicated that HAV was capable of packaging the
606-nt insert coding for the EMCV IRES but that HAV-
IRES was an unstable recombinant virus.
Insertions at both the 2A-2B junction and the 5'NTR
To rule out that constrains at the specific insertion sites
unrelated to packaging limited the viability of the HAV
Rescue and stability of the HAV constructs containing antibi- otic resistance genes in the 2A-2B junction Figure 2
Rescue and stability of the HAV constructs contain-
ing antibiotic resistance genes in the 2A-2B junction. 
(A) Subconfluent FRhK4 cells were transfected with in vitro 
T7 polymerase transcripts of pHAVvec9, pHAVvec9-Bsd, or 
pHAVvec9-GFP-Bsd, or pHAVvec9-Hyg or mock-trans-
fected. Cells were and incubated for 2-weeks in selection 
medium containing 1 μg/ml Bsd for all transfections except 
for cells transfected with pHAVvec9-Hyg transcripts, which 
were grown in the presence of 100 μg/ml Hyg. Phase con-
trast micrographs were taken with a Zeiss Axiovert micro-
scope at 200× magnification. (B) Stability of the recombinant 
HAV. Viral RNA was extracted and fragments were amplified 
by RT-PCR using HAV primers forward VP1 coding for nts 
2928-2951 and reverse 2B primer coding for nts 3715-3738. 
RT-PCR fragments amplified from RNA extracted from 
HAV/7 (lane 1), HAVvec9 (lane 2), HAVvec9-Bsd passage 1 
(lane 3), and HAVvec9-Bsd passage 25-times in the presence 
(lane 4) or absence (lane 5) of Bsd were analyzed by TAE-1%-
agarose gel electrophoresis. The RT-PCR fragments from 
HAVvec9-Bsd and HAVvec9 are indicated by arrowheads 
and their sizes given in base pairs (bp). The size of the DNA 
molecular weight markers (lane M) is indicated in bp.Virology Journal 2009, 6:204 http://www.virologyj.com/content/6/1/204
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constructs, we cloned both the Bsd resistance gene into
the 2A-2B junction and the EMCV IRES into the 5' NTR
(Figure 5). T7 polymerase in vitro transcripts of the result-
ing construct, pHAVvec9-Bsd-IRES, were transfected into
FRhK4 cells. Transfected cells did not survive selection 1
μg/ml Bsd indicating that HAV did not tolerate the double
insertion. IF analysis of transfected cells grown in the
absence of Bsd selection showed that less than 10% of
cells contained HAV antigens (data not shown). RT-PCR
analysis of RNA extracted from particles purified by sedi-
mentation through a 40% sucrose cushion revealed that
the EMCV IRES and the Bsd resistance gene contained
deletions (Figure 6). Nucleotide sequence analysis of PCR
fragments showed the presence of only 21 nt from the
EMCV IRES at the 5'NTR and 120 nt from the Bsd resist-
ance gene at 2A-2B junction. Interestingly, the polylinker,
3Cpro cleavage sites, and Gly hinge flanking sequences
were preserved. These data indicated that HAV cannot tol-
erate insertions larger than 600 nucleotides, and that this
limitation in size is not due to site-specific restrictions of
the inserted sequences.
Discussion
In this paper we studied the packaging size limit of HAV.
The virus tolerated the insertion of approximately 500 nt
at the 2A-2B junction and 600 nt at the 5'NTR. The inser-
tion of 456-nt fragment coding for a Bsd resistance gene
flanked by 3Cpro cleavage sites was remarkably stable for
25 passages even in the absence of antibiotic. However,
HAV could not accommodate larger inserts in the same
site, and viruses containing GFP-Bsd and Hyg selectable
markers could not be rescued from transfected cells. It
should be pointed out FRhk4 cells transfected with
eukaryotic expression vectors containing the GFP-Bsd and
Hyg resistance genes survived selection with Bsd and Hyg,
respectively. Moreover, FRhK4 cells transfected with an
eukaryotic expression vector containing the GFP-Bsd
fusion protein fluoresced similarly to cells transfected
with a construct containing only GFP (data not shown).
Since HAVvec9-Bsd was very stable, it is unclear why we
could not rescue an HAV construct containing GFP-Bsd.
One simple explanation is that we exceeded the packaging
size limit of HAV. However, cells transfected with
pHAVvec9-GFP-Bsd  in vitro transcripts did not survive
selection with Bsd suggesting that packaging alone was
not the only factor affecting infectivity. Therefore, we
hypothesized that site-specific or sequence-specific con-
straints at the 2A-2B junction site prevented HAV replica-
tion. To test this hypothesis, we introduced a completely
different sequence at another site of the HAV genome. To
that effect, we cloned a 606-nt fragment coding for the
EMCV IRES between the HAV IRES and the initiation
codon of the HAV polyprotein. Because HAV containing
the EMCV IRES was unstable and tended to delete the
insert in a few passages, we limited our study to viruses
produced at the initial passage. The failure to rescue virus
from the construct containing the Bsd resistance gene at
the 2A-2B junction and the EMCV IRES at the 5'NTR indi-
cated that the maximum size of foreign sequences that can
be incorporated into the HAV genome of a viable virus is
Schematic representation of the HAV construct containing the EMCV IRES at the 5'NTR of the HAV genome Figure 3
Schematic representation of the HAV construct containing the EMCV IRES at the 5'NTR of the HAV genome. 
A 606-nt cDNA fragment containing the EMCV IRES was inserted into the HAV 5'NTR between the HAV IRES and the initia-
tion codon (ATG) of the HAV polyprotein. The resulting construct was termed pHAV-IRES, and contained a short synthetic 
polylinker containing KpnI, SnaBI, SacII, EcoRI, and AciI restriction sites followed by nts 278-836 of the EMCV IRES (dashed rec-
tangle) inserted into the XbaI site in VP4 in such a way as to recreate the native initiation codon of the HAV polyprotein. The 
mature HAV proteins and the viral poly (A) tail (AAA) are indicated in the schematic representation of the HAV genome 
organization.
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approximately 600 nt. Our study showed that HAV can
package genomes of approximately 8,100 nt composed of
the full-length genome and an insertion of approximately
600 nt, which can accommodate an additional 200 amino
acid protein into the HAV polyprotein. Although the size
of the extra sequences is somehow limited, HAV could be
used as an expression vector for the development of com-
bination vaccines and delivery of genes to the liver.
Conclusion
In this study we showed that viable HAV can package full-
length viral genomes containing insertions of approxi-
mately 600 nt.
Methods
Cells and viruses
Fetal rhesus monkey kidney (FRhK4) cells, a gift of S.
Emerson, National Institutes of Health (NIH), were
grown in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal bovine serum. The cell culture-
adapted human HM-175 strain of HAV was derived from
an infectious cDNA clone [30], termed HAV/7 [31], and
grown in FRhK-4 cells. Nucleotide positions of the HAV
genome are according to the published HM175 HAV
cDNA sequence [32].
Plasmid constructions
Standard molecular biology methods [33] were used to
construct the HAV recombinants. PCR-based DNA frag-
ments were amplified using expand high fidelity PCR kit
(Roche) in 25 cycles consisting of 95°C for 30 sec, 55°C
for 1 min, and 72°C for 2-3 min. For overlap PCR, DNA
fragments were denatured at 94°C and annealed at 45°C
for 2 min in each step. The blasticidin (Bsd), fusion of
green fluorescent protein with Bsd (GFP-Bsd), and hygro-
mycin (Hyg) resistance genes were generated by PCR with
eliminating the translation initiation (ATG) and termina-
tion codons and introducing 5' SalI and 3' KpnI restriction
sites for cloning into the polylinker at the 2A-2B junction
of the HAV polyprotein in pHAVvec9 [19]. To clone
inserts in-frame at the 2A-2B junction, PCR products and
pHAVvec9 were digested with SalI and KpnI, gel purified,
and ligated. The oligonucleotides used to generate the
PCR fragments are described in Table 1. The sequences
inserted into the HAV geome are described in Table 2.
Constructs were verified by automated nucleotide
sequence analysis. The following plasmids were used in
this work:
pT7HAV contains the infectious cDNA cell culture-
adapted HM-175 strain of HAV under the control of a T7
RNA polymerase promoter in pGEM1, and the in vitro
transcripts were infectious in FRhK4 cells [16].
Rescue and stability of the HAV constructs containing the  EMCV IRES at the 5'NTR Figure 4
Rescue and stability of the HAV constructs contain-
ing the EMCV IRES at the 5'NTR. (A) IF analysis of 
FRhK4 cells transfected with in vitro RNA transcripts from 
pHAVvec9, pHAVvec9-Bsd, or pHAV-IRES or mock-trans-
fected. Cells were fixed with acetone two weeks post-trans-
fection, and stained with anti-HAV neutralizing monoclonal 
antibodies K2-4F2 and K3-4C8 and FITC-conjugated goat 
anti-mouse antibodies. Micrographs were taken with a Zeiss 
microscope at 400× magnification. (B) Analysis of the stabil-
ity of HAV recombinants containing the EMCV IRES. RT-PCR 
analysis of genomic RNA extracted form HAV/7, HAV-IRES, 
HAVvec9-Bsd virions and amplified using primers corre-
sponding to nts 484-507 and 1167-1194 of HAV. As negative 
control, T7 polymerase in vitro transcripts from pHAV-IRES 
were spiked into media, layered on top of a 40% sucrose 
cushion, and sedimented by ultracentrifugation. RNA 
extracted from the pellet was used for the RT-PCR analysis 
(Naked-RNA control). The size of the DNA molecular 
weight markers (lane M) is indicated in bp.Virology Journal 2009, 6:204 http://www.virologyj.com/content/6/1/204
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pHAVvec9 was derived from pT7HAV as described previ-
ously [19]. pHAVvec9 contains a polylinker with unique
SalI, SnaBI, and KpnI restriction sites.
pHAVvec9-Bsd contains Bsd gene cloned into the
polylinker of the HAV cDNA in pHAVvec9 [19].
pHAVvec9-GFP-Bsd contains a GFP-Bsd fusion cloned
into the HAV cDNA polylinker in pHAVvec9. The GFP-
Bsd fusion was amplified by PCR from pTracer-CMV/Bsd
(Invitrogen). To create unique SalI site in GFP-Bsd insert,
a silent substitution mutation (from GTCGAC to GTA-
GAC) was introduced to eliminate SalI site in the GFP
gene sequence using overlap PCR.
pHAVvec9-Hyg contains a Hyg resistance gene cloned into
the HAV cDNA polylinker in pHAVvec9. The Hyg resist-
ance gene was amplified by PCR from pCFB-EGSH (Strat-
agene).
pHAV-IRES contains the EMCV IRES (corresponding to
278-836 nt of the EMCV genome) cloned between the
HAV IRES and the HAV polyprotein initiation codons in
pT7HAV (Figure 3). To construct pHAV-IRES, a 606-nt
cDNA fragment containing nt 278-836 of EMCV flanked
at the 5' end by a XbaI site and at the 3'end by the two tan-
dem initiation codons of the HAV polyprotein and an
XbaI restriction site was amplified from pCITE-1 (Nova-
gen), a plasmid containing the EMCV IRES. This ampli-
fied cDNA fragment was cut with XbaI and cloned into the
unique XbaI site adjacent to the HAV initiation codons in
pT7HAV.
pHAVvec9-Bsd-IRES was constructed by cloning the
EMCV IRES from pHAV-IRES into pHAVvec9-Bsd. To do
so, the 1,783-nt BspEI and BstEII fragment of pHAV-IRES
containing the EMCV IRES was cloned into pHAVvec9-
Bsd cut with BspEI and BstEII at nts 24 and 1194 of the
HAV cDNA, respectively. The resulting construct con-
tained both the EMCV IRES and the 5'NTR and the Bsd
resistance gene at the 2A-2B junction of the HAV cDNA.
In vitro RNA synthesis and transfection
Synthesis of full-length HAV RNA transcripts was per-
formed using T7 RNA polymerase [16]. To do so, plas-
mids were linearized with HaeII, which cuts immediately
downstream of the poly(A) of the HAV cDNA [16,30].
Subconfluent FRhK4 cells in 25-cm2 flasks were trans-
fected with in vitro synthesized RNA transcripts using
DEAE-dextran as facilitator [34] or Lipofectamine 2000
(Invitrogen). After 30 min incubation at room tempera-
ture, fresh media was added to replace transfection solu-
tion and incubated at 35°C. Cells were split weekly into
new flasks, and an aliquot was passed to 8-well chamber
slides for immunofluorescence (IF) analysis. To prepare
viral stocks, monolayers with approximately 80% of the
cells expressing HAV antigens as assessed by IF analysis
were subjected to three freeze-thaw cycles and clarified by
low-speed centrifugation. Supernatants containing the
virus stocks were stored at -70°C.
Schematic representation of the HAV construct containing the EMCV IRES at the 5'NTR and the Bsd resistance gene at the  2A-2B junction Figure 5
Schematic representation of the HAV construct containing the EMCV IRES at the 5'NTR and the Bsd resist-
ance gene at the 2A-2B junction. The EMCV IRES was inserted into the HAV 5'NTR in pHAVvec9-Bsd. The construct 
containing both the EMCV IRES at the 5'NTR and the Bsd resistance gene at the 2A-2B junction was termed pHAVvec9-Bsd-
IRES.
AAA VP2 VP3 VP1
VP4
IRES
2A
2B 2C 3C 3D
3A 3B
EMCV  IRES Bsd
pHAVvec9-Bsd-IRES
Rescue and stability of the HAV constructs containing the  EMCV IRES and Bsd resistance gene Figure 6
Rescue and stability of the HAV constructs contain-
ing the EMCV IRES and Bsd resistance gene. Viral 
RNA was extracted from purified virions and analyzed by 
RT-PCR as described in Figures 2B and 4B.Virology Journal 2009, 6:204 http://www.virologyj.com/content/6/1/204
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Immunofluorescence (IF) analysis
FRhK4 cells were grown in 8-well Permanox chamber
slides (Nunc, Inc.) at 35°C in a CO2 incubator for 24-48
h. Cell culture media was aspirated and the cells were
fixed with cold acetone for 30 min at -20°C. Fixed cell
monolayers were air-dried, blocked with PBS-2% FBS at
room temperature, and stained with a mix of anti-HAV
neutralizing murine monoclonal antibodies K2-4F2 and
K3-2F2 [35] and fluorescein isothiocyanate (FITC)-conju-
gated goat anti-mouse antibody (KPL, Inc). Stained slides
were air-dried, coverslips were mounted with PermaFluor
aqueous medium (Shandon Immunon, PA), and fluores-
cent micrographs were taken with a Zeiss Axioscope
microscope at 400× magnification.
RT-PCR and nucleotide sequence analysis
RNA was extracted from HAV particles using QIAamp
viral RNA mini kit (Qiagen). RT-PCR was carried out
using the Superscript-II enzyme kit (Invitrogen). The
cDNA was synthesized with primers corresponding to
HAV nt position 3715-3738 or 1167-1194. PCR frag-
ments were amplified using primers corresponding to
HAV nts 2928-2951 and 3715-3738 or 484-507 and
1167-1194. Amplified DNA fragments were gel purified,
and sequenced using the ABI Prism BigDye terminator
cycle-sequencing ready reaction kit (Applied Biosystems)
and with ABI Prism (model 3100) analyzer (Applied Bio-
systems).
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Table 1: PCR Primers
Name* PCR Fragment Oligonucleotide Sequence&
Bsd forward (SalI) Bsd 5'-GTCGACGTCGACCAGGCCAAGCCTTTGTCTCAAGAA-3'
Bsd reverse (KpnI) Bsd 5'-CGGTTAGGTACCGCCCTCCCACACATAACCAGAGGG-3'
GFP forward (SalI) GFP-Bsd 5'-GTCGACGTCGACGCCTCCAAAGGAGAAGAACTTTTC-3'
Hyg forward (SalI) Hyg 5'-GTCGACGTCGACAAAAAGCCTGAACTCACCGCGACG-3'
Hyg reverse (KpnI) Hyg 5'-CGGTTAGGTACCGTTAGCCTCCCCCATCTCCCGATC-3'
EMVC IRES forward (XbaI) EMCV IRES 5'-TTAGTCTAGATGGTACCTACGTACCGCGGAATTCCGCCCCTCTCCCTAACGTTA 
CTGGCCGAA-3'
EMVC IRES reverse (XbaI) EMCV IRES 5'-TTTCTAGACATGTTCATATTATCATCGTGTTTTTCAA-3'
*Restriction enzymes in brackets cut the PCR fragment amplified with the oligonucleotides.
&The restriction site in each oligonucleotide is underlined.
Table 2: Insertions in the HAV 2A-2B junction or 5'NTR
Construct Insert Site Size (nt) * Infectivity&
pHAVvec9 polylinker 2A-2B 66 +
pHAVvec9-Bsd Bsd 2A-2B 396 +
pHAVvec9-GFP-Bsd GFP-Bsd 2A-2B 1098 -
pHAVvec9-Hyg Hygromycin 2A-2B 1032 -
pHAV-IRES EMCV IRES 5'NTR 606 +
pHAVvec9-Bsd-IRES Bsd 2A-2B 396 -
EMCV IRES 5'NTR 606
* pHAVvec9-Bsd, pHAVvec9-GFP-Bsd, and pHAVvec9-Hyg, and pHAVvec9-Bsd-IRES contain additional 60-nt corresponding to the polylinker 
inserted at the 2A-2B junction.
&Infectivity (+) or lack of infectivity (-) of the T7 polymerase in vitro synthesized transcripts from the plasmid constructs was assessed in FRhK4 cells 
by IF analysis.Virology Journal 2009, 6:204 http://www.virologyj.com/content/6/1/204
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